283 related articles for article (PubMed ID: 15863619)
1. Caspase inhibition reduces tubular apoptosis and proliferation and slows disease progression in polycystic kidney disease.
Tao Y; Kim J; Faubel S; Wu JC; Falk SA; Schrier RW; Edelstein CL
Proc Natl Acad Sci U S A; 2005 May; 102(19):6954-9. PubMed ID: 15863619
[TBL] [Abstract][Full Text] [Related]
2. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease.
Tao Y; Kim J; Schrier RW; Edelstein CL
J Am Soc Nephrol; 2005 Jan; 16(1):46-51. PubMed ID: 15563559
[TBL] [Abstract][Full Text] [Related]
3. An mTOR kinase inhibitor slows disease progression in a rat model of polycystic kidney disease.
Ravichandran K; Zafar I; Ozkok A; Edelstein CL
Nephrol Dial Transplant; 2015 Jan; 30(1):45-53. PubMed ID: 25239638
[TBL] [Abstract][Full Text] [Related]
4. Caspases, Bcl-2 proteins and apoptosis in autosomal-dominant polycystic kidney disease.
Ecder T; Melnikov VY; Stanley M; Korular D; Lucia MS; Schrier RW; Edelstein CL
Kidney Int; 2002 Apr; 61(4):1220-30. PubMed ID: 11918728
[TBL] [Abstract][Full Text] [Related]
5. Targeting of sodium-glucose cotransporters with phlorizin inhibits polycystic kidney disease progression in Han:SPRD rats.
Wang X; Zhang S; Liu Y; Spichtig D; Kapoor S; Koepsell H; Mohebbi N; Segerer S; Serra AL; Rodriguez D; Devuyst O; Mei C; Wüthrich RP
Kidney Int; 2013 Nov; 84(5):962-8. PubMed ID: 23715121
[TBL] [Abstract][Full Text] [Related]
6. [Effect of a modified low protein and low fat diet on histologic changes and metabolism in kidneys in an experimental model of polycystic kidney disease].
Banković-Calić N; Ogbori MR; Nicman E
Srp Arh Celok Lek; 2002; 130(7-8):251-7. PubMed ID: 12585002
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).
Wahl PR; Serra AL; Le Hir M; Molle KD; Hall MN; Wüthrich RP
Nephrol Dial Transplant; 2006 Mar; 21(3):598-604. PubMed ID: 16221708
[TBL] [Abstract][Full Text] [Related]
8. A new in vitro bioassay for cyst formation by renal cells from an autosomal dominant rat model of polycystic kidney disease.
Pey R; Bach J; Schieren G; Gretz N; Hafner M
In Vitro Cell Dev Biol Anim; 1999; 35(10):571-9. PubMed ID: 10614866
[TBL] [Abstract][Full Text] [Related]
9. The effect of paclitaxel on the progression of polycystic kidney disease in rodents.
Martinez JR; Cowley BD; Gattone VH; Nagao S; Yamaguchi T; Kaneta S; Takahashi H; Grantham JJ
Am J Kidney Dis; 1997 Mar; 29(3):435-44. PubMed ID: 9041221
[TBL] [Abstract][Full Text] [Related]
10. mTORC1/2 and rapamycin in female Han:SPRD rats with polycystic kidney disease.
Belibi F; Ravichandran K; Zafar I; He Z; Edelstein CL
Am J Physiol Renal Physiol; 2011 Jan; 300(1):F236-44. PubMed ID: 20943770
[TBL] [Abstract][Full Text] [Related]
11. Pathways of caspase-mediated apoptosis in autosomal-dominant polycystic kidney disease (ADPKD).
Tao Y; Kim J; Stanley M; He Z; Faubel S; Schrier RW; Edelstein CL
Kidney Int; 2005 Mar; 67(3):909-19. PubMed ID: 15698430
[TBL] [Abstract][Full Text] [Related]
12. Altered ATP-sensitive P2 receptor subtype expression in the Han:SPRD cy/+ rat, a model of autosomal dominant polycystic kidney disease.
Turner CM; Ramesh B; Srai SK; Burnstock G; Unwin RJ
Cells Tissues Organs; 2004; 178(3):168-79. PubMed ID: 15655334
[TBL] [Abstract][Full Text] [Related]
13. Resveratrol delays polycystic kidney disease progression through attenuation of nuclear factor κB-induced inflammation.
Wu M; Gu J; Mei S; Xu D; Jing Y; Yao Q; Chen M; Yang M; Chen S; Yang B; Qi N; Hu H; Wüthrich RP; Mei C
Nephrol Dial Transplant; 2016 Nov; 31(11):1826-1834. PubMed ID: 27190325
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor pathway in rats with autosomal dominant polycystic kidney disease.
Nagao S; Kusaka M; Nishii K; Marunouchi T; Kurahashi H; Takahashi H; Grantham J
J Am Soc Nephrol; 2005 Jul; 16(7):2052-62. PubMed ID: 15888569
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Aerobic Glycolysis Attenuates Disease Progression in Polycystic Kidney Disease.
Riwanto M; Kapoor S; Rodriguez D; Edenhofer I; Segerer S; Wüthrich RP
PLoS One; 2016; 11(1):e0146654. PubMed ID: 26752072
[TBL] [Abstract][Full Text] [Related]
16. Effect of lovastatin on the development of polycystic kidney disease in the Han:SPRD rat.
Gile RD; Cowley BD; Gattone VH; O'Donnell MP; Swan SK; Grantham JJ
Am J Kidney Dis; 1995 Sep; 26(3):501-7. PubMed ID: 7645559
[TBL] [Abstract][Full Text] [Related]
17. Gender and the effect of gonadal hormones on the progression of inherited polycystic kidney disease in rats.
Cowley BD; Rupp JC; Muessel MJ; Gattone VH
Am J Kidney Dis; 1997 Feb; 29(2):265-72. PubMed ID: 9016899
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of [¹⁸F]PFH PET renography to predict future disease progression in a rat model of autosomal dominant polycystic kidney disease.
Pathuri G; Hedrick AF; Awasthi V; Cowley BD; Gali H
Nucl Med Biol; 2016 Jan; 43(1):1-5. PubMed ID: 26702780
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Sodium-Glucose Cotransporter 2 with Dapagliflozin in Han: SPRD Rats with Polycystic Kidney Disease.
Rodriguez D; Kapoor S; Edenhofer I; Segerer S; Riwanto M; Kipar A; Yang M; Mei C; Wüthrich RP
Kidney Blood Press Res; 2015; 40(6):638-47. PubMed ID: 26698317
[TBL] [Abstract][Full Text] [Related]
20. Increased epithelial cell proliferation and abnormal extracellular matrix in rat polycystic kidney disease.
Ramasubbu K; Gretz N; Bachmann S
J Am Soc Nephrol; 1998 Jun; 9(6):937-45. PubMed ID: 9621276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
